Soriot's rumored departure would also leave AstraZeneca open for an acquisition, Fernandez noted. It's likely analysts will look for more color on AstraZeneca's second-quarter earnings conference call, which is scheduled for July 27. RELATED: Why AstraZeneca's Rumored Chief Executive Exit Is Bad Timing Deal May Help Celgene Rival Dow's Merck, Bristol In Cancer Drugs AstraZeneca's Cancer Trial Could Help Out A Rival, Analyst Says